Survivorship Promotion In Reducing IGF-1 Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Breast CancerProstate CancerLung CancerColon CancerMelanoma of SkinEndometrial CancerLiver CancerPancreatic CancerRectal CancerKidney CancerOther Solid Malignant Tumors
Interventions
DRUG

Metformin

Participants will receive metformin, an oral medication for type 2 diabetes.Participants randomized to the metformin intervention will receive metformin up to 2,000 mg per day.Dosing can be flexible, two or three times per day with meals as tolerated for 12 months.

BEHAVIORAL

Coach Directed Behavioral Weight Loss

Behavioral-based telephonic coaching with web-based support to promote healthy lifestyle and weight loss in overweight and obese adults.The goal of this intervention is to achieve at least 5% weight loss in the first six months of the intervention and maintain these improvements through month twelve by meeting dietary and exercise goals

BEHAVIORAL

Self-control weight loss

Trial Locations (1)

21207

Johns Hopkins ProHealth, Baltimore

All Listed Sponsors
collaborator

Maryland Cigarette Restitution Fund

OTHER_GOV

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT02431676 - Survivorship Promotion In Reducing IGF-1 Trial | Biotech Hunter | Biotech Hunter